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The rapid evolution of HIV under selective drug pres-
sure has led to multidrug resistant (MDR) strains that
evade standard therapies. We designed highly
potent HIV-1 protease inhibitors (PIs) using the sub-
strate envelope model, which confines inhibitors
within the consensus volume of natural substrates,
providing inhibitors less susceptible to resistance
because a mutation affecting such inhibitors will
simultaneously affect viral substrate processing.
The designed PIs share a common chemical scaffold
but utilize various moieties that optimally fill the sub-
strate envelope, as confirmed by crystal structures.
The designed PIs retain robust binding to MDR
protease variants and display exceptional antiviral
potencies against different clades of HIV as well as
a panel of 12 drug-resistant viral strains. The sub-
strate envelope model proves to be a powerful strat-
egy to develop potent and robust inhibitors that
avoid drug resistance.
INTRODUCTION
Drug resistance is a major problem in the treatment of patients
with HIV/AIDS. Resistance in HIV occurs when the target enzyme
mutates, leading to less efficient drug binding, but maintains bio-
logic function. Currently, there are 25 US Food and Drug Admin-
istration (FDA)-approved drugs targeting different stages in the
life cycle of HIV, including nine protease inhibitors (PIs; http://
www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/
HIVandAIDSActivities/ucm118915.htm. These drugs, especially
when used in combination as the highly active antiretroviral
therapy (HAART), have improved the quality and life expectancy
of patients with HIV infection (Hogg et al., 1998; Palella et al.,
1998). However, the very high replication rate of the virus and
the lack of an error-proof mechanism in HIV reverse transcrip-1116 Chemistry & Biology 20, 1116–1124, September 19, 2013 ª201tase promote the emergence of drug-resistant viral strains in
patients undergoing therapy. New patients are also infected
with already resistant viruses, which is an added challenge in
the treatment of HIV infection. Thus, novel potent drugs targeting
the drug-resistant viral ensemble are needed for effective treat-
ment of HIV/AIDS.
Various strategies have been used to develop new antiviral PI
therapies against drug-resistant HIV, including increasing the
plasma levels of existing PIs by using a boosting agent (Kempf
et al., 1997; Youle, 2007; Zeldin and Petruschke, 2004) and
developing new PIs using structure-based drug design (Ghosh
et al., 2008; Gulnik and Eissenstat, 2008; Nalam and Schiffer,
2008; Wensing et al., 2010). The design strategy to maximize
the number of hydrogen bonds with the protease backbone led
to the development of highly potent PIs active against drug-resis-
tant HIV (Ghosh et al., 2008, 2009, 2011). PIswith improved resis-
tance profiles were also developed using a solvent anchoring
approach (Cihlar et al., 2006) and utilizing a new lysine sulfon-
amide-based molecular core (Stranix et al., 2003). A more
comprehensive strategy is to incorporate the substrate envelope
constraints in the structure-based drug design. This strategy is
based on the observation that substrates with high sequence
diversity adopt a conserved shape when bound to HIV-1 prote-
ase (Prabu-Jeyabalan et al., 2002). The consensus volume
shared by the bound substrates defines the substrate envelope.
Drug-resistance mutations often occur at sites where the inhibi-
tor protrudes outside the substrate envelope (King et al., 2004a).
Similar observations have recently been demonstrated to be
valid for the HCV NS3/4A protease as well (Romano et al.,
2010, 2012), supporting the generality of the substrate envelope
model. Inhibitors designed to fit within this envelope are likely to
be less susceptible to drug resistance (http://hivdb.Stanford.
edu) because a mutation that impairs inhibitor binding will simul-
taneously affect substrate recognition and protease function.
Previously, we designed and synthesized series of PIs with
and without substrate envelope constraints (Ali et al., 2006,
2010; Altman et al., 2008; Chellappan et al., 2007; Nalam et al.,
2010; Nalam and Schiffer, 2008). These studies revealed that
in contrast to inhibitors designed without any constraint, inhibi-
tors designed to fit within the substrate envelope retain binding3 Elsevier Ltd All rights reserved
Figure 1. Structures of the Designed Protease Inhibitors
(A) The chemical scaffold and P10 and P20 groups of the ten inhibitors.
(B) Superimposed X-ray crystal structures of all ten inhibitors in complex with
WT HIV-1 protease. See also Table S1 for crystallographic statistics.
(C) Fit of inhibitors within the substrate envelope. The substrate envelope is in
blue space filling representation, and the superimposed inhibitors are dis-
played as sticks. Protrusions beyond the substrate envelope are in red.
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HIV-1 Protease Inhibitors to Avoid Drug Resistanceaffinity to drug-resistant HIV-1 protease variants, thereby having
flatter resistance profiles. A careful examination of darunavir
(DRV) binding to HIV-1 protease by free energy analysis sug-
gested that the interactions in the S10 and S20 sites can be
improved by using more hydrophobic P10 and P20 groups to sus-
tain van der Waals contacts to protease variants with active site
mutations (Cai and Schiffer, 2010). In previous structure-activity
relationship (SAR) studies of PI libraries based on the (R)-
(hydroxyethylamino)sulfonamide dipeptide isostere, several
high-affinity moieties were identified for the P2 and P20 positions,
including the bis-tetrahydrofurynyl (bis-THF) group in DRV
(Ghosh et al., 1998). However, most of these studies had the
isobutyl group at the P10 position. We have identified other P10
ligands capable of more extensive van der Waals contacts withChemistry & Biology 20, 1116–112the protease due to enhanced size and flexibility, while still stay-
ing within the substrate envelope (Altman et al., 2008; Nalam
et al., 2010). The challenge is combining these moieties into a
single inhibitor that retains extremely high potency and stays
within the volume of the substrate envelope.
We used the substrate envelope strategy to optimize PIs
based on the DRV scaffold by incorporating ligands at the P10
and P20 positions that fit within the substrate envelope and there-
fore are predicted as promising candidates to be potent inhibi-
tors of multidrug-resistant (MDR) HIV-1 protease variants. In
this study, we report the structure-guided design and synthesis
of a series of such potent inhibitors and their subsequent struc-
tural, biochemical, antiviral, and pharmacokinetic evaluation.
Two chemical moieties at the P10 position and five chemical moi-
eties at the P20 position were incorporated to optimize inhibitor
flexibility and interactions with the protease. The resulting ten
inhibitors (Figure 1) were evaluated for their inhibitory activity
against wild-type (WT) and MDR HIV-1 protease variants, anti-
viral activity against a panel of WT and patient-derived drug
resistant HIV strains, and pharmacokinetic properties. The com-
pounds retain highly potent inhibitory activity against MDR pro-
tease variants, display exceptional potency against a panel of
12 MDR strains in antiviral assays, and overall perform better
than the most potent FDA-approved inhibitor, DRV. Crystal
structures of complexes with WT HIV-1 protease reveal that
the inhibitors indeed fit within the substrate envelope as
designed and support the use of substrate envelope constraints
in the design of potent inhibitors evading resistance.
RESULTS
Inhibitor Design and Synthesis
The design strategy for high-affinity inhibitors against drug-resis-
tant HIV-1 protease variants was based on three criteria: The
inhibitors should (1) fit within the substrate envelope; (2) be
based on the scaffold of a known high-affinity inhibitor; and (3)
have optimized P10 and P20 groups to retain contacts with the
protease with drug-resistance mutations.
The primary constraint in the design of inhibitors was proper fit
within the substrate envelope of HIV-1 protease. This approach
aims to minimize susceptibility to resistance because a mutation
that affects inhibitor binding will simultaneously affect substrate
affinity (King et al., 2004a). In accord with the second criterion,
the design was based on the (R)-(hydroxyethylamino)sulfon-
amide dipeptide isostere, the shared core scaffold of APV and
DRV. Finally, different chemical moieties were introduced at
the P10 and P20 positions. As the isobutyl P10 moiety in DRV loses
van der Waals contacts with the protease variants containing
drug-resistance mutations I50V, V82A, and I84V (King et al.,
2004b), two P10 ligands, (S)-2-methylbutyl (isopentyl) and
2-ethyl-n-butyl (isohexyl), with enhanced flexibility and steric
volume were probed to enable sustained contacts with the pro-
tease. The combination of these two P10 ligands with five P20
ligands that satisfy the substrate envelope constraints yielded
ten inhibitors (Figure 1). The P20 moieties were selected based
on the previous structure-activity studies in the DRV series and
our computational library designs, and include 4-aminobenzene,
4-methoxybenzene, 4-(hydroxymethyl)benzene, 1,3-benzodiox-
olane, and benzothiazole (Altman et al., 2008; Ghosh et al., 2008;4, September 19, 2013 ª2013 Elsevier Ltd All rights reserved 1117
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Figure 2. Synthesis of Protease Inhibitors
Reagents and conditions: (a) R1NH2, EtOH, 80
C, 3 hr; (b) aq. Na2CO3, CH2Cl2, 0C to room temperature (rt), overnight; (c) CH2Cl2, Et3N, 0C to rt, overnight; (d)
NaBH4, MeOH, 0
C, 15 min; (e) TFA, CH2Cl2, 1 hr; (f) Py, p-NO2-PhOCOCl, 0C to rt, 24 hr; (g) DIEA, CH3CN, 0C to rt, 24 hr; (h) SnCl2.2H2O, EtOAc, 70C, 3 hr.
See Supplemental Experimental Procedures for more details.
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following the synthetic route illustrated in Figure 2. Briefly, ring
opening of chiral epoxide 1 with primary amines 2a–b provided
the amino alcohols 3 and 4. Reactions of sulfonyl chlorides
5a–e with 3 and 4 gave the intermediate (R)-(hydroxyethyla-
mino)sulfonamides 6–7. Boc deprotection followed by the reac-
tions of the free amines with bis-THF carbonate 9, prepared from
chiral bis-THF alcohol 8, provided the target compound series
10a–e and 11a–e.
The Designed Compounds Inhibit WT and
Drug-Resistant Protease Variants
The enzyme inhibition constants (Ki values) of the designed
inhibitors were determined against WT and three drug-resistant
HIV-1 protease variants, along with all nine FDA-approved PIs
(Figure 3; Table S2 available online). TwoMDR protease variants
(M1: L10I/G48V/I54V/L63P/V82A; M2: L10I/L63P/A71V/G73S/
I84V/L90M) represent the pattern of resistance mutations that
occur under the selective pressure of three or more currently
prescribed PIs in patients with HIV-1 infection (Wu et al., 2003).
The third variant (M3: I50V/A71V) is a signature-resistant variant
of APV/DRV, which shares the same scaffold used in the design
of the ten inhibitors.
All designed inhibitors were highly potent in inhibiting enzyme
activity, with Ki values in the 0.2–30 pM range against WT prote-
ase. Five PIs had sub-pM Ki values (PIs 10c, 10d, 11b, 11c, and
11d;Ki = 0.2–0.9 pM). Seven of the nine FDA-approved drugs are
two to three orders of magnitude weaker inhibitors of WT prote-
ase (Ki = 46–284 pM), while two are low picomolar binders (LPV
and DRV, Ki = 5 pM). The precise measurements of Ki values in
the low pM range using standard biochemical assays are limited
(Gulnik and Eissenstat, 2008; Kuzmic, 1996; Miller et al., 2006).
This makes direct comparison of these PIs with DRV, and each
other, challenging, as all have Ki values in the low pM range.1118 Chemistry & Biology 20, 1116–1124, September 19, 2013 ª201With those caveats, some of these PIs have Ki values against
WT protease an order of magnitude lower than the most potent
FDA-approved drug DRV (Ki = 5 pM).
The PIs also retained potency against MDR variants of HIV-1
protease. The Ki values for all PIs against the three MDR prote-
ases (M1, M2, and M3) were in the pM range. Most FDA-
approved PIs lose significant potency against M1 and M2,
except DRV and tipranavir (Figure 3; Table S2). All the PIs re-
tained potent activity against theM1 variant with Ki values com-
parable to or lower than DRV (M1 Ki = 25 pM), in particular three
PIs (10b, 11b, and 11c) had Ki values lower than DRV. Similarly,
most PIs inhibited the M2 variant with potency comparable to
DRV. The M3 protease variant contains signature mutations of
DRV resistance (I50V and A71V). Compared to WT protease,
M3 susceptibility to DRV was 50-fold decreased, with a Ki of
245 pM. In contrast, the designed inhibitors exhibited better po-
tency against M3, with Ki values consistently lower than that of
DRV, and as low as 6 pM for PIs 10a and 11d (Figure 3). Thus,
this design strategy yielded highly potent PIs that retain enzyme
inhibition activity against MDR variants of HIV-1 protease.
Overall, replacement of the P10 isobutyl group of DRV with
larger, more flexible isopentyl and isohexyl groups resulted in
improved inhibition of drug-resistant protease variants. This is
evident from better potency of PIs 10a and 11a, which incorpo-
rate the same 4-aminobenzene group at P20 as DRV. The modi-
fications at the P10 position also proved to be advantageous
when combined with other groups at the P20 position. In partic-
ular, PIs 10c and 11c with the 4-(hydroxymethyl)benzene P20
group were highly potent inhibitors of WT protease and retained
low pM activity against resistant variants. Thus, incorporation of
optimized ligands that can retain interactions with drug-resis-
tance protease variants coupled with the substrate envelope
constraint proved to be a useful strategy for designing robust
inhibitors.3 Elsevier Ltd All rights reserved
Figure 3. Binding Affinities of APV, DRV,
and the Ten Designed Protease Inhibitors
to WT and Drug-Resistant Variants of
HIV-1 Protease
Inhibitory activity was determined by a FRET-
based enzymatic assay; Ki values are the average
of at least three independent measurements.
See also Table S2.
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Enhanced Protease Contacts
The crystal structures of the ten potent inhibitors were deter-
mined in complex with WT HIV-1 protease. The crystals
diffracted to 1.45–1.95 A˚, yielding high-resolution complex
structures. The crystallographic and refinement statistics, as
well as Protein Data Bank (PDB) accession codes for all of the
structures are listed in Table S1.
The co-crystal structures of all ten PIs in complex with the
protease superimpose with each other extremely well (Fig-
ure 1B). The protease backbone is very similar in all the com-
plexes, with a root-mean-square deviation (rmsd) of 0.11–
0.16 A˚ for Ca atoms. Even the protease side chains, including
those in the active site, have similar conformations in all
the crystal structures, except minor local changes in side
chain conformations surrounding the different P10 and P20
groups. These tight-binding PIs ‘‘lock’’ into the active site and
induce a tightly shared rigid protease conformation with little
variability.
Except for the chemically diverse P10 and P20 groups, the
inhibitors superimpose very well in all the crystal structures
and fit well within the substrate envelope (Figure 1C). Despite
inherent flexibility, the P10 isopentyl and isohexyl groups adopt
the same conformation in all the complexes, similar to the isobu-
tyl group in DRV bound to protease (Figure 4A). The key differ-
ence is the enhanced van der Waals contacts of the longer
isopentyl (displayed for PI 10a in Figure 4B) and isohexyl (dis-
played for PI 11a in Figure 4C) groups within the S10 pocket of
the protease active site, compared to those of the isobutyl group
of DRV. The P10 group makes vdW interactions with the hydro-
phobic residues I50, P81, V82, and I84 in the active site of the
protease. With the exception of P81, these residues are key sites
of multidrug resistance, and mutate to those with smaller side
chains (Ile to Val, Val to Ala) to confer resistance, such as in
the case of I50Vmutation in the DRV signature-resistance variant
M3. The isopentyl and isohexyl groups in the PIs fill the S10
pocket better compared to the isobutyl group of DRV, and their
flexibility makes them capable of adapting and forming van der
Waals contacts even with the mutated shorter side chain resi-
dues. These enhanced contacts are consistent with retained
affinities to drug-resistant HIV protease variants with mutations
around the S10 pocket (Figure 3; Table S2).Chemistry & Biology 20, 1116–1124, September 19, 2013 ªImproved Antiviral Activity against
WT and Drug-Resistant HIV Strains
The PIs were tested for antiviral activity
against WT HIV from clades A, B, and C,
as well as a diverse panel of 12 clinically
relevant patient-derived drug-resistant
viruses using PhenoSense HIV assays(Monogram Biosciences, San Francisco, CA) and compared
with DRV (Figure 5; Table S3; Figure S1). The average half-
maximal effective concentration (EC50) values against all 12
viral variants tested and fold changes in potency with respect
to WT strain were used to evaluate PI resistance profiles
(Table S3).
All ten inhibitors exhibited subnanomolar potency against WT
virus from three different clades (EC50 = 0.04–0.4 nM). PIs 10b,
10d, and 11b are more potent against WT clade B virus
compared to DRV (EC50 = 0.4 nM).
The designed PIs even retained antiviral potency against
MDR strains, further validating the enzymatic assays. The
average EC50 values against 12 different drug-resistant strains
were lower than those for DRV for all ten PIs (Table S3; Fig-
ure 5). Overall, the PIs were 1.5–4.5 times more potent than
DRV against drug-resistant HIV strains tested. There was no
significant difference in the EC50 values of PIs with the isopentyl
(10a–d) versus the isohexyl (11a–d) group at the P10 position.
However, the P20 phenylsulfonamide groups appear to have
more effect on the potency against drug-resistant strains.
Thus, consistent with previous SAR results in the DRV series
(Surleraux et al., 2005a), compounds with the 4-methoxyben-
zene (10b and 11b) and 1,3-benzodioxolane (10d and 11d)
groups at the P20 position exhibited better potency than the
corresponding 4-aminobenzene analogs 10a and 11a. How-
ever, in contrast to the corresponding DRV analog (Ghosh
et al., 2008), PIs with the 4-(hydroxymethyl)benzene P20 group
(10c and 11c) also exhibited highly potent activity, likely due
to the increased lipophilicity. In a previous study, HIV PIs
with cLogP values in the 3.7–5.0 range exhibited antiviral
potencies against drug-resistant HIV variants better than DRV
(cLogP = 2.88; Miller et al., 2006). Because the cLogP values
of the PIs are all in the desired range (Table S4), the
increased lipophilicities, in addition to other factors, may be
contributing to the improved antiviral potencies compared to
those of DRV.
DRV retains low nanomolar activity against most MDR strains,
but loses significant potency against two MDR strains with the
I50V proteasemutation. However, a number of the PIs retain bet-
ter potency against these MDR strains, particularly compounds
10b and 10d with the 4-methoxybenzene and 1,3-benzodioxo-
lane groups at the P20 position. In fact, compound 10b retains2013 Elsevier Ltd All rights reserved 1119
Figure 4. Comparison of van der Waals
Contacts with the Protease for P10 Groups
in PIs
(A) Superposition of DRV, PI 10a, and PI 11a
structures bound to WT HIV-1 protease.
(B) Isobutyl P10 group in DRV.
(C and D) Isopentyl P10 group in PI 10a (C), iso-
hexyl P10 group in PI 11a (D). The longer P10
groups make enhanced van der Waals contacts
with the protease.
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tested and low nanomolar potency against the strains with the
I50V protease mutation, exhibiting the lowest average EC50 of
1.33 nM compared to 5.98 nM for DRV. Thus, the combination
of isopentyl group at P10 and 4-methoxybenzene group at P20
provided the compound (10b) with the best resistance profile.
The excellent resistance profiles of the PIs indicate that the
design strategy of filling the subsites without violating the sub-
strate envelope constraints was successful in optimizing the
inhibitor for robustness against resistance mutations.
In Vitro Pharmacokinetic Evaluation
The exciting PhenoSense resistance profile data prompted
further evaluation of the PIs as potential drug candidates using1120 Chemistry & Biology 20, 1116–1124, September 19, 2013 ª2013 Elsevier Ltd All rights rin vitro pharmacokinetic assays. The
aqueous solubility, plasma protein bind-
ing, plasma stability, and microsomal
stability in rat and human liver micro-
somes of all PIs were determined by
Apredica (Watertown, MA) using DRV as
a control (Tables 1 and S4).
The oral bioavailability of a drug
depends in part on water solubility
and lipophilicity. The latter is estimated
by the calculated partition coefficient
cLogP, which is optimized to balance
between aqueous solubility and transport
through the hydrophobic cell membrane
(Miller et al., 2006). Compounds with
cLogP values in the 3.5–5.0 range have
been reported to have the best antiviral
activity as HIV PIs (Miller et al., 2006).
The cLogP values of the PIs are all in the
desired range (Table S4). In fact, they
have higher lipophilicities compared to
DRV, which may enhance cell penetra-
tion. Despite the enhanced lipophilicity,
the PIs also have good aqueous solubi-
lity except the PIs 10b and 11b with the
methoxybenzene group at the P20 posi-
tion. Overall, the increased lipophilicity
and reasonable aqueous solubility likely
contribute to the improved antiviral
activity profiles (EC50 values), which
depend on both the intrinsic binding
affinity to the target (Ki), and the transport
efficiency into the cell.The metabolic stability of PIs was evaluated by measuring the
microsomal stability, plasma stability, and plasma protein bind-
ing (Tables 1 and S4). Assays were performed in rat and human
microsomes to determine the stability of PIs at 15-, 30-, and
60-min time points and in the absence and presence of the
CYP-450 inhibitor ritonavir (RTV; Table 1). Similar to DRV, RTV
boosting considerably enhanced the microsomal stability for
the majority of the PIs, which were otherwise not stable in the
presence of liver microsomes at 60 min. Interestingly, two inhib-
itors with the benzothiazole P20 moiety (10e and 11e) showed
excellent stability in both rat and human microsomal tests
even without RTV boosting. Overall, the PIs have good pharma-
cokinetic properties, encouraging their further development as
drug candidates.eserved
Figure 5. Resistance Profiles of DRV and
the Ten PIs that Were Designed
Antiviral potencies (EC50 values) were obtained for
WT HIV from clades A, B, and C, and 12 different
patient-derived drug-resistant variants of the
virus. The PhenoSense HIV assays were per-
formed by Monogram Biosciences.
See also Table S3 and Figure S1.
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With the emergence of resistance, many drugs become obsolete
in the clinic against rapidly evolving disease targets, such as in
the case of HIV/AIDS. In HIV infection, error-prone reverse tran-
scriptase and the high replication rates of the virus result in a
diverse viral population, among which drug-resistant viral strains
are selected under the pressure of drug therapy. To avoid
spending time and resources in developing drugs that rapidly
become obsolete, strategies at the initial design stage need to
be implemented to minimize the chances of subsequent drug
resistance.
The substrate envelope model provides a framework for im-
plementing drug resistance considerations into structure-based
drug design. For drug resistance to occur, the target needs to be
able to carry out its biologic function while at the same time
avoiding drug binding. The chances of this happening are dimin-
ished if the designed drug binds the target similarly to the natural
substrates. Protrusions beyond the substrate envelope cause
vulnerable sites for drug-resistance mutations (King et al.,
2004a) because mutations into bulkier side chains impact drug
binding without affecting the substrates.
The results presented here demonstrate that optimally filling
the substrate envelope is essential to developing potent inhibi-
tors. In cases where the designed drug occupies a smaller vol-
ume than the substrates, mutations into shorter side chains
may diminish van der Waals interactions with the inhibitor, while
still maintaining sufficient interactions with the larger natural sub-
strates. In the DRV signature-resistant HIV-1 protease variant,
the I50V mutation causes loss of contacts with the P10 isobutyl
group. The longer isopentyl and isohexyl moieties introduced
here to the P10 site optimally fill the substrate envelope and
have flexibility, which enables sustaining van der Waals interac-
tions even when resistant mutations occur. Thus, the inhibitors
have improved van der Waals contacts with the protease while
still staying within the substrate envelope and retain potency
against a wider variety of HIV-1 protease mutants.Chemistry & Biology 20, 1116–1124, September 19, 2013 ªThe improved binding affinities of PIs
against drug-resistant protease variants
correlate with their exceptional antiviral
potencies against a panel of 12 patient-
derived drug resistant HIV strains in
PhenoSense HIV assays. The PIs retain
better antiviral potency against MDR
HIV variants less susceptible to DRV,
with EC50 values in the low nanomolar
range. However, MDR viruses insensitive
to DRV are also relatively less sensitive
to designed PIs, implying the same fac-tors may render the inhibitors less effective in the antiviral
assays. The MDR viruses insensitive to DRV and the ten PIs
contain a combination of protease secondary mutations outside
the active site, which may interdependently confer resistance to
all these inhibitors. Such secondary mutations may alter the
processivity of the protease to favor substrate processing over
inhibitor binding, thereby decreasing susceptibility to inhibitors
(Chang and Torbett, 2011; Muzammil et al., 2003; Xie et al.,
1999). Thus, the compensatory mutations outside the protease
active site may also be contributing toward the observed resis-
tance profiles.
All ten inhibitor-protease complex structures superimpose
extremely well with each other, despite chemical diversity at
the P10 and P20 sites of the inhibitors. The exceptionally high
affinity of the designed sub- and low-picomolar inhibitors may
be locking the protease structure and not allowing much confor-
mational variability. Future studies of PI complex dynamics will
provide insights into the effect of sub-picomolar binders on the
protease conformational and dynamic behavior.
In conclusion, in quickly evolving therapeutic targets, restrict-
ing inhibitors to fit within the substrate envelope is a key factor in
minimizing the susceptibility to drug resistance.
SIGNIFICANCE
Overcoming resistance is crucial in designing robust drugs
against HIV/AIDS. Resistance to direct-acting antiviral
drugs, including HIV-1 protease inhibitors, occurs when
the target mutates to avoid drug binding, while maintaining
activity on substrates. Our design strategy of optimizing in-
hibitor fit within the substrate envelope yielded high-affinity
inhibitors of multidrug resistant HIV protease variants,
which exhibited improved antiviral potencies as compared
to DRV against a large panel of drug-resistant HIV strains.
Some of these potent inhibitors also have promising phar-
macokinetic profiles, even in the absence of a boosting
agent, encouraging their potential development as drugs.2013 Elsevier Ltd All rights reserved 1121
Table 1. Microsomal Stability Profile of Protease Inhibitors
Compound RTV
Microsomal Stability (avg. % fraction remaining)
Microsomal CLint
(ml/min/mg) Microsomal T1/2 (min)
at 30 min at 60 min
Human Rat Human RatHuman Rat Human Rat
10a  42 24 19 9 81 129 26 16
+ 81 51 66 35 21 67 99 31
10b  0 0 0 0 776 885 3 2
+ 79 0 68 0 19 518 110 4
10c  0 0 0 0 590 664 4 3
+ 93 45 89 22 8 79 >180 26
10d  9 0 4 0 232 987 9 2
+ 80 0 60 0 24 771 85 3
10e  32 64 33 31 82 53 25 40
+ 86 71 62 74 21 20 99 106
11a  50 13 26 2 69 204 30 10
+ 87 30 71 11 16 117 126 18
11b  0 18 0 19 844 150 2 14
+ 75 50 66 20 23 74 90 28
11c  0 0 0 0 829 907 3 2
+ 64 79 69 57 26 27 81 78
11d  0 0 0 0 617 712 3 3
+ 55 21 46 4 46 156 45 13
11e  100 84 83 87 7 9 >180 >180
+ 96 62 95 44 3 44 >180 48
DRV  37 40 13 23 101 83 21 25
+ 100 84 100 65 0 20 >180 103
RTV, ritonavir; CLint, microsomal intrinsic clearance; T1/2, half-life.
See also Table S4.
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strate envelope constraints in the initial stages of drug
design as a powerful strategy to design potent inhibitors
that evade resistance. Drug resistance extends well beyond
HIV, thwarting the success ofmany drugs to quickly evolving
targets in pathogens and cancer. This strategy is broadly
applicable to the design of inhibitors against such quickly
evolving disease targets, facilitating a more rational and
rapid selection of drug candidates that are robust and thus
less susceptible to resistance.EXPERIMENTAL PROCEDURES
Protein Crystallography
The expression, isolation, and purification of wild-type and mutant HIV-1 pro-
teases used for crystallization and binding experiments were carried out as
previously described (King et al., 2002). Cocrystals of the inhibitors with the
WT protease were grown at room temperature by hanging drop vapor diffusion
method. Protease concentration of 1.6 mg/ml with 3-fold molar excess of in-
hibitors was used to set the crystallization drops with the reservoir solution
consisting of 126 mM phosphate buffer at pH 6.2, 63 mM sodium citrate,
and 24%–29% ammonium sulfate.
The crystals used for data collection were mounted in MitegenMicromounts
and flash-frozen over a nitrogen stream. Intensity data for complex structures
of 10a, 10b, 10d, 10e, 11b, 11c, and 11d were collected at 80C on an in-
house Rigaku X-ray generator equipped with an R-axis IV image plate. One1122 Chemistry & Biology 20, 1116–1124, September 19, 2013 ª201hundred eighty frames were collected per crystal with an angular separation
of 1 and no overlap between frames. The data processing of the frames
was carried out using the programs DENZO and ScalePack, respectively
(Minor, 1993; Otwinowski et al., 1997). Intensity data for 10c, 22a, and 11e
were collected under cryogenic conditions at the BioCARS 14-BMC beamline
at Argonne National Laboratory (Advanced Photon Source, Argonne, IL).
Diffraction images were indexed and scaled using the program HKL2000
(Otwinowski et al., 1997).
The crystal structures were solved and refined with the programs within the
CCP4 interface (CCP4, 1994). Structure solutions for all the WT PI complexes
were obtained with the molecular replacement package AMoRe (Navaza,
1994) using 1F7A (Prabu-Jeyabalan et al., 2000) as the starting model. Upon
obtaining solution, the molecular replacement phases were further improved
using ARP/wARP (Morris et al., 2002) to build solvent molecules into the unac-
counted regions of electron density. Model building was performed using the
interactive graphics program Coot (Emsley and Cowtan, 2004). Conjugate
gradient refinement using Refmac5 (Murshudov et al., 1997) was performed
by incorporating Schomaker and Trueblood tensor formulation of TLS (trans-
lation, libration, screw-rotation) parameters (Kuriyan and Weis, 1991; Scho-
maker and Trueblood, 1968; Tickle and Moss, 1999). The working R (Rfactor)
and its cross-validation (Rfree) were monitored throughout the refinement.
The data collection and refinement statistics are shown in Table S5.
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